Regulation & law · 21/09/2023

National Cancer Institute to Grant Exclusive Patent License for Engineered T Cell Therapies for HPV-Positive Cancer

The National Cancer Institute, part of the National Institutes of Health, is considering granting an exclusive patent license to Scarlet TCR, Inc. for the development and commercialization of engineered T cell therapies for treating HPV-positive cancers.